|
| 37098238 | Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. | J Clin Oncol | 2023 |
| 37973789 | Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma. | | 2023 |
| 36749880 | Impact of Genomic and Clinical Factors on Outcome of Children â¿¥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. | | 2023 |
| 35211994 | Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. | EMBO J | 2022 |
| 35646475 | tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. | OncoImmunology | 2022 |
| 34781268 | Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2021 |
| 33479234 | Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. | Nature Communications | 2021 |
| 33739795 | Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. | Am J Surg Pathol | 2021 |
| 33565241 | BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. | Pediatr Blood Cancer | 2021 |
| 33823167 | Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. | Transplant Cell Ther | 2021 |
| 34319759 | Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. | J Clin Oncol | 2021 |
| 33918978 | A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. | Cancers (Basel) | 2021 |
| 33205902 | A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. | Pediatr Blood Cancer | 2021 |
| 33056981 | Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. | Nat Commun | 2020 |
| 32315273 | Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. | J Clin Oncol | 2020 |
| 32179872 | Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency. | Pediatr Res | 2020 |
| 32060267 | MYCN amplification and ATRX mutations are incompatible in neuroblastoma. | Nat Commun | 2020 |
| 31758088 | Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. | Leukemia | 2020 |
| 32275099 | The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur. | Pediatr Blood Cancer | 2020 |
| 32457760 | Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. | Frontiers in Immunology | 2020 |
| 32492633 | Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. | Eur J Cancer | 2020 |
| 32653773 | Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. | Eur J Cancer | 2020 |
| 32931402 | Reply to K. Beiske et al. | J Clin Oncol | 2020 |
| 32903140 | Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. | J Clin Oncol | 2020 |
| 31454045 | Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. | JAMA | 2019 |
| 30479064 | The challenge of defining "ultra-high-risk" neuroblastoma. | Pediatr Blood Cancer | 2019 |
| 30700572 | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. | Sci Transl Med | 2019 |
| 30914792 | Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. | Leukemia | 2019 |
| 29799508 | Myc, Oncogenic Protein Translation, and the Role of Polyamines. | | 2018 |
| 28972044 | Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. | Clin Cancer Res | 2018 |
| 30380416 | TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. | Cell Rep | 2018 |
| 30518699 | Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. | JCI Insight | 2018 |
| 30652588 | Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. | JCO clinical cancer informatics | 2018 |
| 29393340 | Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours. | International Journal of Oncology | 2018 |
| 29514301 | Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. | J Natl Cancer Inst | 2018 |
| 29376112 | Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. | Lancet Child Adolesc Health | 2018 |
| 29464082 | MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. | Oncotarget | 2017 |
| 28974650 | Inhibition of the oncogenic fusion protein EWS-FLI1 causes G<sub>2</sub>-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. | Sci Signal | 2017 |
| 28659916 | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. | Front Immunol | 2017 |
| 28696504 | Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. | Cancer | 2017 |
| 27513929 | Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. | PLoS One | 2016 |
| 27012811 | Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. | Clin Cancer Res | 2016 |
| 27009842 | Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. | Oncotarget | 2016 |
| 27044383 | Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. | Eur J Nucl Med Mol Imaging | 2016 |
| 27351283 | A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma. | Oncotarget | 2016 |
| 26338179 | Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. | Eur J Nucl Med Mol Imaging | 2016 |
| 26035700 | Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. | Br J Cancer | 2015 |
| 25756510 | EGFR signaling defines Mclâ»1 survival dependency in neuroblastoma. | Cancer Biology and Therapy | 2015 |
| 25911508 | Expanding MYCN's reach in oncogenic transcription. | Journal of the National Cancer Institute | 2015 |
| 25475555 | TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. | Cancer Letters | 2015 |